Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients (RACHEL)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00931320 |
Recruitment Status
:
Completed
First Posted
: July 2, 2009
Last Update Posted
: October 27, 2009
|
Sponsor:
AstraZeneca
Information provided by:
AstraZeneca
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date | June 30, 2009 | |||
First Posted Date | July 2, 2009 | |||
Last Update Posted Date | October 27, 2009 | |||
Study Start Date | July 2009 | |||
Primary Completion Date | Not Provided | |||
Current Primary Outcome Measures |
Evaluate current LDL/HDL ratio in Korean patients (between baseline & after treatment) [ Time Frame: After Treatment : at least 4 weeks before statin taking /Baseline : no limitation. ] | |||
Original Primary Outcome Measures | Same as current | |||
Change History | Complete list of historical versions of study NCT00931320 on ClinicalTrials.gov Archive Site | |||
Current Secondary Outcome Measures |
Evaluate difference of LDL/HDL ratio among different statins & dosages (between baseline & after treatment) [ Time Frame: After Treatment : at least 4 weeks before statin taking / Baseline : no limitation. ] | |||
Original Secondary Outcome Measures | Same as current | |||
Current Other Outcome Measures | Not Provided | |||
Original Other Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title | Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients | |||
Official Title | Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients | |||
Brief Summary | An observational, non-interventional, multi-centre study to provide further information on the ratio of LDL-C to HDL-C improvement after statin treatment in Korean patients group. | |||
Detailed Description | Not Provided | |||
Study Type | Observational | |||
Study Design | Observational Model: Cohort Time Perspective: Retrospective |
|||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Not Provided | |||
Sampling Method | Non-Probability Sample | |||
Study Population | Who have at least made 1 visit to the outpatient clinic within previous 6 months . | |||
Condition | Dyslipidemias | |||
Intervention | Not Provided | |||
Study Groups/Cohorts | 3000 patients
Who have at least made 1 visit to the outpatient clinic within previous 6 months . |
|||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status | Completed | |||
Estimated Enrollment |
3000 | |||
Original Estimated Enrollment | Same as current | |||
Actual Study Completion Date | September 2009 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
|
|||
Sex/Gender |
|
|||
Ages | 18 Years and older (Adult, Senior) | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | Not Provided | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT00931320 | |||
Other Study ID Numbers | NIS-CKR-DUM-2009/3 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | Hyunah Caroline, Choi / CV TA Physician, AstraZeneca Pharmaceuticals | |||
Study Sponsor | AstraZeneca | |||
Collaborators | Not Provided | |||
Investigators |
|
|||
PRS Account | AstraZeneca | |||
Verification Date | October 2009 |